RITUXIMAB, BUT NOT A CHANGE FROM IMVP (IFOSFAMIDE ...

The reason for putting this regimen as the preferred first choice is that it can be given in the out patient setting and has an improved toxicity profile compared to the more standard regimens such as R-ESHAP. However, clinicians may chose to use in-patient regimens in specific patients where agreed by the lymphoma MDT. ................
................

In order to avoid copyright disputes, this page is only a partial summary.